August 11, 2018, Gmax Biopharm, a clinical stage biopharmaceutical company focusing on therapeutic antibody development targeting GPCRs, announced today that GMA102 has been approved by Center for Drug Evaluation (CDE, CFDA) for the IND of type 2 diabetes (T2D).

GMA102 is a long-acting GLP-1R antibody developed from Gmax’s proprietary GPCR antibody platform, for the treatment of type 2 diabetes and obesity. It is now in phase 2 clinical trial in Australia and New Zealand. Preliminary data from the phase 2 study demonstrated promising blood glucose and body weight lowering effects of Glutazumab on T2D patients. With the long half-life more than 1 week, GMA102 is potentially to be developed as a bi-weekly/monthly dosing GLP-1 agonist product. 

GMA102 was selected as the national “Mega-Innovative Program” in China. Leveraging the ongoing phase 2 study in Australia, GMA102 is expected to accelerate the clinical development in China.